Topical herbal extract (Huangdang mixture) exhibits both preventive and therapeutic effects in murine acute irritant contact dermatitis

International Journal of Dermatology

Volumn 50, Issue 11, 2011, Pages 1421-1427

  Man, Wenyan ^a   Man, Mona ^a   Hupe, Melanie ^a   Martin Ezquerra, Gemma ^b   Feingold, Kenneth R ^a   Elias, Peter M ^a   Man, Mao Qiang ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 2,4 DINITROBENZENE; ALISMATIS EXTRACT; ANGELICA EXTRACT; ANTIINFLAMMATORY AGENT; HUANGDANG MIXTURE; OXAZOLONE; PAEONLAE RUBRA EXTRACT; PHELLODENDRON EXTRACT; PHORBOL ESTER; PLANT EXTRACT; SMILACIS GLABRAE EXTRACT; SWORDLIKE EXTRACT; UNCLASSIFIED DRUG;

ACUTE IRRITANT CONTACT DERMATITIS; ANGELICA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHINESE MEDICINE; CONTROLLED STUDY; CORK TREE; FEMALE; IRRITANT DERMATITIS; MEDICINAL PLANT; MOUSE; NONHUMAN; PAEONLAE RUBRA; RHIZOME; SKIN ALLERGY;

ANALYSIS OF VARIANCE; ANIMALS; DERMATITIS, ALLERGIC CONTACT; DERMATITIS, IRRITANT; DISEASE MODELS, ANIMAL; DRUGS, CHINESE HERBAL; FEMALE; MICE; MICE, INBRED C57BL; OXAZOLONE; TETRADECANOYLPHORBOL ACETATE;

EID: 80054790977     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2011.04970.x     Document Type: Article

References (68)

1. Man MQ, Hatano Y, Lee SH, et al. Characterization of a hapten-induced, murine model with multiple features of atopic dermatitis: structural, immunologic, and biochemical changes following single versus multiple oxazolone challenges. J Invest Dermatol 2008; 128: 79-86.
2. Scharschmidt TC, Man MQ, Hatano Y, et al. Filaggrin deficiency confers a paracellular barrier abnormality that reduces inflammatory thresholds to irritants and haptens. J Allergy Clin Immunol 2009; 124: 496-506.
3. Brandt C, Pavlovic V, Radbruch A, et al. Low-dose cyclosporine A therapy increases the regulatory T cell population in patients with atopic dermatitis. Allergy 2009; 64: 1588-1596.
4. Hijnen DJ, ten Berge O, Timmer-de Mik L, et al. Efficacy and safety of long-term treatment with cyclosporin A for atopic dermatitis. J Eur Acad Dermatol Venereol 2007; 21: 85-89.
5. Jacob SE. Cyclosporin ophthalmic emulsion - a novel therapy for benzyl alcohol-associated eyelid dermatitis. Contact Dermatitis 2008; 58: 169-170.
6. Hijnen DJ, Knol E, Bruijnzeel-Koomen C, de Bruin-Weller M. Cyclosporin A treatment is associated with increased serum immunoglobulin E levels in a subgroup of atopic dermatitis patients. Dermatitis 2007; 18: 163-165.
7. Korstanje MJ, Bilo HJG, Stoof TJ. Sustained renal function loss in psoriasis patients after withdrawal of low dose cyclosporin therapy. Br J Dermatol 1992; 127: 501-504.
8. Powles AV, Hardman CM, Porter WM, et al. Renal function after 10years treatment with cyclosporin for psoriasis. Br J Dermatol 1998; 138: 443-449.
9. Markham T, Watson A, Rogers S. Adverse effects with long-term cyclosporin for severe psoriasis. Clin Exp Dermatol 2002; 27: 111-114.
10. Kirby B, Rogers S. Gingival hyperplasia in psoriasis patients treated with cyclosporin. Clin Exp Dermatol 2000; 25: 97-98.
11. Gonçalves SC, Díaz-Serrano KV, de Queiroz AM, et al. Gingival overgrowth in a renal transplant recipient using cyclosporine A. J Dent Child (Chic) 2008; 75: 313-317.
12. Oettinger-Barak O, Machtei EE, Peled M, et al. Cyclosporine A-induced gingival hyperplasia pemphigus vulgaris: literature review and report of a case. J Periodontol 2000; 71: 650-656.
13. V'lckova-Laskoska MT. Cyclosporin A-induced gingival hyperplasia in psoriasis: review of literature and case reports. Acta Dermatovenerol Croat 2005; 13: 108-113.
14. Miyagi S, Sekiguchi S, Kawagishi N, et al. Parkinsonism during cyclosporine treatment in liver transplantation: an unusual case report. Transplant Proc 2008; 40: 2823-2824.
15. Lima MA, Maradei S, Maranhao Filho P. Cyclosporine-induced parkinsonism. J Neurol 2009; 256: 674-675.
16. Marchiori PE, Mies S, Scaff M. Cyclosporine A-induced ocular opsoclonus and reversible leukoencephalopathy after orthotopic liver transplantation: brief report. Clin Neuropharmacol 2004; 27: 195-197.
17. Ruzicka T, Bieber T, Schöpf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997; 337: 816-821.
18. Hanifin JM, Ling MR, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol 2001; 44: S28-S38.
19. Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 1998; 102: 637-644.
20. Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001; 44: S58-S64.
21. Simmonds J, Dewar C, Dawkins H, et al. Tacrolimus in pediatric heart transplantation: ameliorated side effects in the steroid-free, statin era. Clin Transplant 2009; 23: 415-419.
22. Weischer M, Röcken M, Berneburg M. Calcineurin inhibitors and rapamycin: cancer protection or promotion? Exp Dermatol 2007; 16: 385-393.
23. Arellano FM, Wentworth CE, Arana A, et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007; 127: 808-816.
24. Kim M, Jung M, Hong SP, et al. Topical calcineurin inhibitors compromise stratum corneum integrity, epidermal permeability and antimicrobial barrier function. Exp Dermatol 2010; 19: 501-510.
25. Kolbe L, Kligman AM, Schreiner V, Stoudemayer T. Corticosteroid-induced atrophy and barrier impairment measured by non-invasive methods in human skin. Skin Res Technol 2001; 7: 73-77.
26. Kao JS, Fluhr JW, Man MQ, et al. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities. J Invest Dermatol 2003; 120: 456-464.
27. Kumaran MS, Kaur I, Kumar B. Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo. J Eur Acad Dermatol Venereol 2006; 20: 269-273.
28. Kragballe K, Austad J, Barnes L, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol 2006; 154: 1155-1160.
29. Ahn SK, Bak HN, Park BD, et al. Effects of a multilamellar emulsion on glucocorticoid-induced epidermal atrophy and barrier impairment. J Dermatol 2006; 33: 80-90.
30. Jensen JM, Pfeiffer S, Witt M, et al. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol 2009; 123: 1124-1133.
31. Jacobi A, Antoni C, Manger B, et al. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2005; 52: 522-526.
32. Cassano N, Loconsole F, Coviello C, Vena GA. Infliximab in recalcitrant severe atopic eczema associated with contact allergy. Int J Immunopathol Pharmacol 2006; 19: 237-240.
33. Hegde N, Gayomali C, Rich MW. Infliximab-induced headache and infliximab-induced meningitis: two ends of the same spectrum? South Med J 2005; 98: 564-566.
34. Asarch A, Gottlieb AB, Lee J, et al. Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J Am Acad Dermatol 2009; 61: 104-111.
35. Pirard D, Arco D, Debrouckere V, Heenen M. Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: three further cases and current overview. Dermatology 2006; 213: 182-186.
36. Cohen JD, Bournerias I, Buffard V, et al. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J Rheumatol 2007; 34: 380-385.
37. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44: 265-267.
38. Yang XG, Chen DY, Lin J, Du Y. Modulatory effect of the oral liquid expelling wind and stopping itching on Th1/Th2 cytokines in patients with dermatitis and eczema (in Chinese). Chin J Dermatovenereol 2005; 19: 307-308.
39. Shang JW. Surveying the curative effect on the ointment of Qi can Lian to treat the eczema of the dermatitis (in Chinese). Chin J Dermatovenereol 2007; 21: 448.
40. Zhang XM, Lv DH, Zhang XM. Clinical observation of the therapeutic effect of Jinzhijieyinhansuye liquid on patients with dermatitis and eczema (in Chinese). Chin J Dermatovenereol 2006; 20: 220-221.
41. Lee HS, Kim SK, Han JB, et al. Inhibitory effects of Rumex japonicus Houtt on the development of atopic dermatitis-like skin lesions in NC/Nga mice. Br J Dermatol 2006; 155: 33-38.
42. Taniguchi Y, Kohno K, Inoue S, et al. Oral administration of royal jelly inhibits the development of atopic dermatitis-like skin lesions in NC/Nga mice. Int Immunopharmacol 2003; 3: 1313-1324.
43. Choi MS, Kim EC, Lee HS, et al. Inhibitory effects of Saururus chinensis [LOUR.] BAILL on the development of atopic dermatitis-like skin lesions in NC/Nga mice. Biol Pharm Bull 2008; 31: 51-56.
44. Kim DY, Jung JA, Kim TH, et al. Oral administration of Uncariae rhynchophylla inhibits the development of DNFB-induced atopic dermatitis-like skin lesions via IFN-gamma down-regulation in NC/Nga mice. J Ethnopharmacol 2009; 122: 567-572.
45. Lv HL. Treatment of atopic dermatitis with Danggui Dihuang: a 31 case report (in Chinese). Shangdong J Trad Chin Med 2002; 21: 474.
46. Man M, Elias PM, Man W, et al. The role of CD44 in cutaneous inflammation. Exp Dermatol 2009; 18: 962-969.
47. Sheu MY, Fowler AJ, Kao J, et al. Topical peroxisome proliferator activated receptor-α activators reduce inflammation in irritant and allergic contact dermatitis models. J Invest Dermatol 2002; 118: 94-101.
48. Tu CX, Lin XR, Gu L. The effects of 4 traditional Chinese herbal medicinal compounds on murine DNFB dermatitis (in Chinese). Chin J Dermatol 1998; 31: 244-246.
49. Jian D, Chen X, Du QJ, et al. The clinical efficacy of winona moisturizing products in the treatment of atopic dermatitis (in Chinese). J Clin Dermatol 2009; 38: 367-369.
50. Long LP, Bai YP, Liu YS, et al. Observation on the effect of glycyrrhizin complex on subacute and chronic eczema (in Chinese). Chin Pharmacy 2003; 14: 37-38.
51. Cui SH, Li T. Clinical analysis of 400 eczema/atopic dermatitis subjects treated with tablet containing common Threewingnut root and Glycyrrhizin. J Dermatol Venereol (in Chinese) 2007; 29: 37-38.
52. Zhang YF, Chen QS, Wang P, et al. Clinical study on atopic dermatitis treated with ShengQiJiangzhuo drink. Chin Med Herald (in Chinese) 2007; 4: 85-86.
53. Lee SJ, Oh SG, Seo SW, et al. Oral administration of Astragalus membranaceus inhibits the development of DNFB-induced dermatitis in NC/Nga mice. Biol Pharm Bull 2007; 30: 1468-1471.
54. Ukawa Y, Izumi Y, Ohbuchi T, et al. Oral administration of the extract from Hatakeshimeji (Lyophyllum decastes sing.) mushroom inhibits the development of atopic dermatitis-like skin lesions in NC/Nga mice. J Nutr Sci Vitaminol (Tokyo) 2007; 53: 293-296.
55. Iguchi T, Kawata A, Watanabe T, et al. Fermented barley extract suppresses the development of atopic dermatitis-like skin lesions in NC/Nga mice, probably by inhibiting inflammatory cytokines. Biosci Biotechnol Biochem 2009; 73: 489-493.
56. Man MQ, Shi Y, Man M, et al. Chinese herbal medicine (Tuhuai extract) exhibits topical anti-proliferative and anti-inflammatory activity in murine disease models. Exp Dermatol 2008; 17: 681-687.
57. Qin CZ, Shi JS. Clinical study on atopic dermatitis treated with WenQing drink (in Chinese). Chin Foreign Med Treatment 2008; 27: 55-56.
58. Dong BH. Clinical observation on the treatment of 156 diaper dermatitis with Cicao-Huangbo ointment (in Chinese). J Chin Modern Trad Chin Med 2006; 2: 369-370.
59. Li WY, Xie WP, Deng SG, Xuan GW. Effects of YangXieZhiYang tablet on DNF-induced contact dermatitis (in Chinese). Herald Med 2003; 22: 838-840.
60. Li F, Luo WH. Summary of 44 atopic dermatitis subjects treated with Chinese and Western medicine (in Chinese). Hunan J Trad Chin Med 2006; 22: 20-21.
61. Zheng YQ, Wei W, Zhu L, Liu JX. Effects and mechanisms of Paeoniflorin, a bioactive glucoside from paeony root, on adjuvant arthritis in rats. Inflamm Res 2007; 56: 182-188.
62. Xu HM, Wei W, Jia XY, et al. Effects and mechanisms of total glucosides of paeony on adjuvant arthritis in rats. J Ethnopharmacol 2007; 109: 442-448.
63. Jiang J, Xu Q. Immunomodulatory activity of the aqueous extract from rhizome of Smilax glabra in the later phase of adjuvant-induced arthritis in rats. J Ethnopharmacol 2003; 85: 53-59.
64. Xie CH, Zhang MS, Zhou YF, et al. Chinese medicine Angelica sinensis suppresses radiation-induced expression of TNF-alpha and TGF-beta1 in mice. Oncol Rep 2006; 15: 1429-1436.
65. Wang J, Du JR, Wang Y, et al. Z-ligustilide attenuates lipopolysaccharide-induced proinflammatory response via inhibiting NF-kappaB pathway in primary rat microglia. Acta Pharmacol Sin 2010; 31: 791-797.
66. Zhang C, Zhou A, Zhang M. Chemical constituents of Alisma orientalis and their immunosuppressive function (in Chinese). Zhongguo Zhong Yao Za Zhi 2009; 34: 994-998.
67. Zhao YY, Cheng XL, Zhang Y, et al. Simultaneous determination of eight major steroids from Polyporus umbellatus by high-performance liquid chromatography coupled with mass spectrometry detections. Biomed Chromatogr 2010; 24: 222-230.
68. Li CY, Wang C, Wei W. Effects and sectional mechanisms of total glucosides of paeony on mice with chronic dermatitis-eczema (in Chinese). Chin Pharmacol Bull 2008; 24: 1366-1369.